Octreotide

Revision as of 19:56, 27 September 2011 by WikiBot (talk | contribs) (Protected "Octreotide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Octreotide
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Intramuscular, intravenous
ATC code
Pharmacokinetic data
Bioavailability100%; I.M: 60% to 63% of subcutaneous dose
Protein binding65%
MetabolismHepatic
Elimination half-life1.7-1.9 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC49H66N10O10S2
Molar mass1019.24 g/mol

WikiDoc Resources for Octreotide

Articles

Most recent articles on Octreotide

Most cited articles on Octreotide

Review articles on Octreotide

Articles on Octreotide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Octreotide

Images of Octreotide

Photos of Octreotide

Podcasts & MP3s on Octreotide

Videos on Octreotide

Evidence Based Medicine

Cochrane Collaboration on Octreotide

Bandolier on Octreotide

TRIP on Octreotide

Clinical Trials

Ongoing Trials on Octreotide at Clinical Trials.gov

Trial results on Octreotide

Clinical Trials on Octreotide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Octreotide

NICE Guidance on Octreotide

NHS PRODIGY Guidance

FDA on Octreotide

CDC on Octreotide

Books

Books on Octreotide

News

Octreotide in the news

Be alerted to news on Octreotide

News trends on Octreotide

Commentary

Blogs on Octreotide

Definitions

Definitions of Octreotide

Patient Resources / Community

Patient resources on Octreotide

Discussion groups on Octreotide

Patient Handouts on Octreotide

Directions to Hospitals Treating Octreotide

Risk calculators and risk factors for Octreotide

Healthcare Provider Resources

Symptoms of Octreotide

Causes & Risk Factors for Octreotide

Diagnostic studies for Octreotide

Treatment of Octreotide

Continuing Medical Education (CME)

CME Programs on Octreotide

International

Octreotide en Espanol

Octreotide en Francais

Business

Octreotide in the Marketplace

Patents on Octreotide

Experimental / Informatics

List of terms related to Octreotide

Octreotide (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.

Effects

Somatostatin has numerous physiological effects:

Uses

The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, the treatment of diarrhea and flushing episodes associated with carcinoid syndrome, and treatment of diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas).

Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea overdose.

Octreotide has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion.

In patients with suspected esophageal varices, octreotide can be given to help decrease bleeding.

Octreotide has been investigated for patients with pain from chronic pancreatitis.[1]

References

  1. Uhl W, Anghelacopoulos SE, Friess H, Büchler MW (1999). "The role of octreotide and somatostatin in acute and chronic pancreatitis". Digestion. 60 Suppl 2: 23–31. PMID 10207228.
  • Katzung, Bertram G. (ed.), ed. (2004). Basic and Clinical Pharmacology. Stamford, Conn: Lange Medical Books/McGraw Hill. ISBN 0-07-141092-9.

External links

Template:Pituitary and hypothalamic hormones and analogues Template:SIB de:Octreotid

Template:WikiDoc Sources